Precision oncology matches each patient with the therapy most likely to work, based on the molecular profile of their tumor. For molecular labs, that means turning somatic NGS data into reliable, actionable results: detecting SNVs, indels and CNVs, and assessing genomic signatures such as HRD, MSI and TMB that guide treatment decisions.
In this section, we share our latest articles on precision oncology: case studies from labs using SeqOne for somatic analysis, scientific insights on biomarkers like homologous recombination deficiency, and updates on how our platform helps teams deliver faster, clinically validated cancer reports.
DiagAI uses inheritance & quality rules based on real diagnostic data, enabling clinicians to understand AI recommendations and collaborate on system improvement.